Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf415 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Maria Ines Figueroa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Fundación Huésped, Ciudad de Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Lamivudine, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
Dolutegravir (DTG)/lamivudine dual therapy (DT) has demonstrated noninferiority to triple therapy (TT) in the GEMINI trials. Although the population with ≤200 CD4 cells/mm3 had a lower response rate, this was unrelated to virological failure. This trial evaluated the antiviral activity of dolutegravir/lamivudine among antiretroviral therapy (ART)-naive patients with human immunodeficiency virus (HIV) with a CD4 count ≤200 cells/mm3.
Methods
DOLCE is a randomized, hypothesis-based, open-label, multicenter study l, assessing the antiviral efficacy of DTG/3TC at week 48 in treatment-naive people with HIV (PWH) with CD4 counts ≤200 cells/mm3. Participants were randomly assigned in a 2:1 ratio to receive DTG/3TC as a single tablet regimen or DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC). The primary endpoint was the proportion of participants with pVL <50 copies/mL at week 48 (Food and Drug Administration snapshot analysis intent-to-treat exposed population). This report presents results at week 48.
Results
Baseline characteristics were similar in both arms. In the DT arm, median CD4 cell count was 109 cells/mm (interquartile range [IQR]: 49–177) and median pVL was 180,000 copies/mL (IQR: 53 309–468 691); 45.4% had CD4 <100 cells/mm3, and 61.4% had pVL >100 000 copies/mL. CDC (Centers for Disease Control and Prevention) stage C: 31.4%. At week 48, virological suppression (pVL <50 copies/mL) was achieved 82.2% in the DT (125/152), and the CD4 count increased by +200 cells/mm3. Per-protocol analysis showed a response rate of 91.9%. Severe adverse events (n = 17) were reported in 15 of 152 participants (11.1%).
Conclusions
Dolutegravir/3TC demonstrated high efficacy in a population with low CD4 counts and high viral load. This study adds information regarding the efficacy and safety of DTG/3TC, regardless of baseline CD4 counts and viral load. Clinical Trials Registration NCT04880395.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Department, Fundación Huésped, Ciudad de Buenos Aires, Argentina.
- Infectious Diseases Department, Fundação Bahiana de Infectologia, Salvador, Bahia, Brazil.
- Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia/EBSERH, Salvador, Brazil.
- Infectious Diseases Division, Hospital General de Agudos Dr. Cosme Argerich, Ciudad de Buenos Aires, Argentina.
- Infectious Diseases Department, Hospital Geral de Nova Iguaçu, Nova Iguaçu, Rio de Janeiro, Brazil.
- AIDS and Molecular Immunology Laboratory, IOC/FIOCRUZ, Rio de Janeiro, Brazil.
ORCID-Profile: Carlos Brites, Diego Cecchini, Marcus Lacerda, Maria Jose Rolon, Eduardo Sprinz, Pedro Cahn
Zitieren
APA
Figueroa, M. I., Brites, C., Cecchini, D., Ramalho, A., Francos, J. L., Lacerda, M., Rolon, M. J., Madruga, J. V., Sprinz, E., Souza, T. N. L., Parenti, P., Converso, D., Mernies, G., Sued, O., Cahn, P., & DOLCE study group (2026). Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf415
Vancouver
Figueroa MI, Brites C, Cecchini D, Ramalho A, Francos JL, Lacerda M, et al. Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf415
BibTeX
@article{Figueroa2026,
author = {Figueroa, Maria Ines and Brites, Carlos and Cecchini, Diego and Ramalho, Aline and Francos, Jose Luis and Lacerda, Marcus and Rolon, Maria Jose and Madruga, Jose Valdez and Sprinz, Eduardo and Souza, Tamara Newman Lobato and Parenti, Pablo and Converso, Daniela and Mernies, Gissella and Sued, Omar and Cahn, Pedro and DOLCE study group, DOLCE study group},
title = {Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf415}
}
EUVIMED